IL17A and psoriasis: In a retrospective, multicenter, and multinational study, the tolerability and safety of IL-17 and IL-23 inhibitors were evaluated in patients with psoriasis with newly diagnosed LTBI who received no treatment and in those who received chemoprophylaxis for TB.